Online inquiry

IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9233MR)

This product GTTS-WQ9233MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets MUC1 gene. The antibody can be applied in Pancreatic Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9233MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1318MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABT-700
GTTS-WQ12943MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PankoMab
GTTS-WQ8104MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ2257MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ3655MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ5236MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ12272MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MRA
GTTS-WQ14398MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW